MX2014013039A - Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. - Google Patents
Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.Info
- Publication number
- MX2014013039A MX2014013039A MX2014013039A MX2014013039A MX2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A MX 2014013039 A MX2014013039 A MX 2014013039A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple sclerosis
- treating
- human patient
- laquinimod
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/039090 WO2013166166A1 (en) | 2012-05-02 | 2013-05-01 | Use of high dose laquinimod for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013039A true MX2014013039A (es) | 2015-02-04 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013039A MX2014013039A (es) | 2012-05-02 | 2013-05-01 | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (enExample) |
| EP (1) | EP2844255A4 (enExample) |
| JP (2) | JP2015515985A (enExample) |
| KR (1) | KR20150013658A (enExample) |
| CN (2) | CN104284663A (enExample) |
| AR (1) | AR090885A1 (enExample) |
| AU (1) | AU2013256352A1 (enExample) |
| BR (1) | BR112014027010A2 (enExample) |
| CA (1) | CA2870684A1 (enExample) |
| CL (1) | CL2014002935A1 (enExample) |
| EA (1) | EA201492010A1 (enExample) |
| HK (1) | HK1206246A1 (enExample) |
| IL (1) | IL235337A0 (enExample) |
| MX (1) | MX2014013039A (enExample) |
| PE (1) | PE20150161A1 (enExample) |
| PH (1) | PH12014502447A1 (enExample) |
| SG (1) | SG11201406594UA (enExample) |
| TW (2) | TW201804997A (enExample) |
| UY (1) | UY34775A (enExample) |
| WO (1) | WO2013166166A1 (enExample) |
| ZA (1) | ZA201408820B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| PE20151435A1 (es) * | 2012-10-12 | 2015-10-15 | Teva Pharma | Laquinimod para reducir el dano talamico en la esclerosis multiple |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| HK1218254A1 (zh) * | 2013-02-15 | 2017-02-10 | Teva Pharmaceutical Industries Ltd. | 用拉喹莫德治疗多发性硬化症 |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| SG11201608674UA (en) * | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| ES2572811T3 (es) * | 2004-09-09 | 2016-06-02 | Yeda Research And Development Co., Ltd. | Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| BR112012000568A2 (pt) * | 2009-06-19 | 2015-10-06 | Teva Pharma | tratamento da esclerose múltipla com laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| JP2014530821A (ja) * | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
| HK1218254A1 (zh) * | 2013-02-15 | 2017-02-10 | Teva Pharmaceutical Industries Ltd. | 用拉喹莫德治疗多发性硬化症 |
-
2013
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en not_active Ceased
- 2013-05-01 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Withdrawn
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017222691A (ja) | 2017-12-21 |
| EP2844255A4 (en) | 2015-10-14 |
| JP2015515985A (ja) | 2015-06-04 |
| TW201804997A (zh) | 2018-02-16 |
| CL2014002935A1 (es) | 2015-03-06 |
| HK1206246A1 (en) | 2016-01-08 |
| AU2013256352A1 (en) | 2014-11-27 |
| KR20150013658A (ko) | 2015-02-05 |
| CN105832733A (zh) | 2016-08-10 |
| ZA201408820B (en) | 2016-06-29 |
| US20160000775A1 (en) | 2016-01-07 |
| WO2013166166A1 (en) | 2013-11-07 |
| US20150265592A1 (en) | 2015-09-24 |
| US20130303569A1 (en) | 2013-11-14 |
| AR090885A1 (es) | 2014-12-10 |
| CN104284663A (zh) | 2015-01-14 |
| TW201347762A (zh) | 2013-12-01 |
| PH12014502447A1 (en) | 2015-01-12 |
| UY34775A (es) | 2013-11-29 |
| EP2844255A1 (en) | 2015-03-11 |
| SG11201406594UA (en) | 2014-11-27 |
| PE20150161A1 (es) | 2015-02-22 |
| BR112014027010A2 (pt) | 2017-06-27 |
| EA201492010A1 (ru) | 2015-06-30 |
| IL235337A0 (en) | 2014-12-31 |
| CA2870684A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| JP2016505050A5 (enExample) | ||
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| BR112012020415A2 (pt) | composição farmacêutica para a prevenção ou tratamento da osteoartrite | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| NZ599227A (en) | Therapeutic agent for chronic pain | |
| CY1117605T1 (el) | Θεραπεια της ασθενειας crohn me laquinimod | |
| UA58482U (ru) | Способ антибиотикотерапии инфекционных осложнений после искусственного прерывания беременности |